Prostate Warriors

We share updates on the latest advancements in advanced prostate
cancer research.

[Prostate Warriors @ProstateWars]

Zanzalintinib for Metastatic Castration-Resistant Prostate Cancer https://t.co/19fdAugkFp

[Prostate Warriors @ProstateWars]

Phase 3 CaBRA Trial: Adding Carboplatin for mHSPC With BRCA Mutations or Neuroendocrine Phenotype https://t.co/YjmxnNAkaA

[Prostate Warriors @ProstateWars]

Scientists Identify SIRT1 as a Driver of Neuroendocrine Prostate Cancer https://t.co/nBrmr1j407

[Prostate Warriors @ProstateWars]

B7-H3 ADC YL201 Delivers Encouraging Results in Advanced mCRPC https://t.co/KdlHzHHFOC

[Prostate Warriors @ProstateWars]

Phase 1/2 Trial: Epigenetic KAT6 Inhibitor Plus Darolutamide in mCRPC https://t.co/x2kaSzxEXW

[Prostate Warriors @ProstateWars]

A-DREAM Trial Suggests Some Men with Metastatic Prostate Cancer May Stop Therapy Safely for a Time https://t.co/NI31YOcDKz

[Prostate Warriors @ProstateWars]

Phase 2 TALENT Trial: Talazoparib as Monotherapy or With Enzalutamide in HRR-deficient mCRPC https://t.co/fa3BSzXqKm

[Prostate Warriors @ProstateWars]

ABBV-969 in mCRPC: Dual‑Targeting ADC Shows Robust PSA and Objective Responses in Heavily Pretreated Patients https://t.co/uLKBYcGkQ2

[Prostate Warriors @ProstateWars]

CONVERGE-01: CONV01-α Shows Activity After Lu-PSMA in mCRPC https://t.co/RXy2TQQhQHα-shows-activity-after-lu-psma-in-mcrpc/

[Prostate Warriors @ProstateWars]

Overcoming AR Mutations in Prostate Cancer: Phase 1 Results of HRS-5041 https://t.co/KmR3Ehh37v

[Prostate Warriors @ProstateWars]

BAT Before Sipuleucel-T in mCRPC: Immune Priming? https://t.co/MA8jpBn6Do

[Prostate Warriors @ProstateWars]

ARPI Doublet vs Triplet Therapy in Metastatic Prostate Cancer: Real‑World Survival and the Role of PSA Nadir https://t.co/mNk8p6Zkss

[Prostate Warriors @ProstateWars]

Emerging Real-World Evidence Suggests Differential Outcomes Between Abiraterone and Darolutamide in Hormone-Sensitive Prostate Cancer https://t.co/VkGs0z5rbh

[Prostate Warriors @ProstateWars]

Darolutamide Linked to Cognitive Benefit Over Enzalutamide in Prostate Cancer https://t.co/PVzQAg3GEn

[Prostate Warriors @ProstateWars]

CT‑Measured Muscle Quality Predicts Survival in Men with Non‑Metastatic Castration‑Resistant Prostate Cancer https://t.co/bcJAENuem9

[Prostate Warriors @ProstateWars]

When Scans Stay Stable: How Progression‑Free Survival Reflects Survival in mCRPC https://t.co/oCmuccen90

[Prostate Warriors @ProstateWars]

Phase 3 PSMAddition Trial Reports Positive Outcomes for mHSPC https://t.co/m8Qgo3UniX

[Prostate Warriors @ProstateWars]

ARASEC Trial Validates Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer https://t.co/Hr9vkwXOt3

[Prostate Warriors @ProstateWars]

Telmisartan: A Familiar Blood Pressure Pill with New Potential in Cancer Therapy https://t.co/NhZ9yERxpD

[Prostate Warriors @ProstateWars]

Targeted Alpha Therapy Plus PARP Blockade: AZD2265 plus AZD9574 for Advanced Prostate Cancer https://t.co/BfHOdJ91cD